September 21st 2020
The addition of durvalumab to tremelimumab showed modest activity in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins.
Frontline pembrolizumab plus chemotherapy significantly improved overall survival, progression-free survival, and objective response rates compared with chemotherapy alone in patients with locally advanced unresectable or metastatic esophageal cancer.
September 20th 2020
Lenvatinib plus pembrolizumab showed early antitumor activity and tolerability in previously treated patients with advanced solid tumors.
The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors.
Overall survival was significantly improved in patients who received hepatic arterial infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization.
John Zalcberg, PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.
September 19th 2020
The novel broad-spectrum KIT and PDGFRα inhibitor ripretinib continued to demonstrate clinically meaningful benefit as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumors.
Improvements in disease-free survival and progression-free survival were observed in patients with progressive pancreatic or midgut neuroendocrine tumors whose frequency of dosing for lanreotide Autogel was increased from 120 mg every 28 days to every 14 days.
September 17th 2020
In an interim analysis of a subset of patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements, futibatinib was shown to be efficacious and tolerable.
Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.
